Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 9480 | 8.42 |
09:33 ET | 7537 | 8.36 |
09:35 ET | 1824 | 8.21 |
09:37 ET | 200 | 8.315 |
09:39 ET | 220 | 8.2397 |
09:42 ET | 10607 | 8.33 |
09:44 ET | 925 | 8.375 |
09:46 ET | 899 | 8.38 |
09:48 ET | 2200 | 8.35 |
09:50 ET | 500 | 8.38 |
09:51 ET | 180 | 8.38 |
09:53 ET | 444 | 8.41 |
09:55 ET | 1820 | 8.44 |
09:57 ET | 2609 | 8.41 |
10:00 ET | 420 | 8.439 |
10:02 ET | 2521 | 8.475 |
10:04 ET | 1374 | 8.54 |
10:06 ET | 941 | 8.58 |
10:08 ET | 4390 | 8.62 |
10:09 ET | 8217 | 8.655 |
10:11 ET | 3752 | 8.66 |
10:13 ET | 4590 | 8.63 |
10:15 ET | 5771 | 8.655 |
10:18 ET | 100 | 8.6101 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.1B | -2.2x | --- |
Zymeworks Inc | 981.5M | -9.3x | --- |
Gyre Therapeutics Inc | 1.1B | -52.5x | --- |
Immatics NV | 936.9M | -12.4x | --- |
Poseida Therapeutics Inc | 912.3M | -14.8x | --- |
Nurix Therapeutics Inc | 1.5B | -7.2x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
---|---|
Revenue (TTM) | $78.6M |
Shares Outstanding | 137.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-3.92 |
Book Value | $11.80 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 14.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -774.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.